Pfizer's crizotinib given pre-launch to some patients in Japan
This article was originally published in Scrip
Executive Summary
In an unusual move, Pfizer's first-in-class drug crizotinib has been made available to a small group of lung cancer sufferers in Japan ahead of its official launch.